Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...

Historically, the most common treatment for wet macular degeneration involved anti-vascular endothelial growth factor injections, such as Avastin, Lucentis, and Eylea. These drugs work by blocking ...

Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili, its biosimilar to Eylea. The agreement allows Biocon ...

The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...

Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending appeal at the United States Court of Appeals for the Federal Circuit (USCAFC) of patent US11084865 ('865 patent) ...

Biocon Biologics Ltd, a subsidiary of Biocon Limited, announced a major achievement through a settlement and license agreement with Regeneron to launch Yesafili in the US market as an interchangeable ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

Eylea does not have any known drug interactions. However, it’s still important to talk with your doctor about all medications, supplements, and vitamins you use before starting treatment with ...

The global Age-Related Macular Degeneration (AMD) Market is poised for significant expansion over the next decade, with its value expected to grow from US$ 11.31 billion in 2023 to US$ 19.72 billion ...